All News Releases

Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2012 Results on Thursday, February 14, 2013
1/31/13
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and year ended December 31, 2012 on Thursday, February 14, 2013 before the US financial markets open. Following the release of the financial results, Alexion management will conduct a conference call and audio web cast on Thursday, February 14, 2013, at 10:00 a.m. Eastern Time (ET). To participate inmore...
Alexion to Present at the JP Morgan 31st Annual Healthcare Conference
1/2/13
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the JP Morgan 31st Annual Healthcare Conference in San Francisco at 9:00 a.m. Pacific time (12:00 p.m. Eastern time) on Monday, January 7, 2013. An audio webcast of Dr. Bell’s remarks will be available live. You can access the webcast at: www.alexionpharma.com. An archived versionmore...
New Data Highlighting Long-Term Efficacy and Safety Outcomes of PNH Patients Treated with Soliris® Reported at ASH Annual Meeting
12/10/12
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of new data demonstrating the long-term benefits of Soliris® (eculizumab) in patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare and life-threatening blood disorder characterized by complement-mediated hemolysis (destruction of red blood cells). Data including the clinical benefits of Soliris in the treatment of patients with PNH andmore...
Alexion to Present at the 24th Annual Piper Jaffray Healthcare Conference
11/21/12
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the 24th Annual Piper Jaffray Healthcare Conference in New York City at 2:30 p.m. Eastern time on Wednesday, November 28, 2012. An audio webcast of Dr. Bell’s remarks will be available live. You can access the webcast at: www.alexionpharma.com. An archived version of the remarksmore...
Alexion Announces $400 Million Share Repurchase Program
11/8/12
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) (Alexion or the Company) today announced that the Company’s Board of Directors has authorized the repurchase of up to $400 million of Alexion common stock. Under the program, purchases may be made from time to time on the open market, or through privately negotiated transactions, block transactions, or other techniques, as determined by the Company’s management and in accordance withmore...
Researchers to Present Additional Data on Soliris® (eculizumab) as a Treatment for Patients with PNH and aHUS at ASH Annual Meeting
11/7/12
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers will present data from clinical studies of Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two debilitating, ultra-rare and life-threatening disorders, at the 54th Annual Meeting of the American Society of Hematology (ASH). Abstracts summarizing these data are published onmore...
Two-Year Data Show Long-Term Benefits of Chronic Soliris® Therapy in Patients with aHUS
11/3/12
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of two-year data that highlight the long-term benefits of chronic Soliris® (eculizumab) therapy in patients with atypical hemolytic uremic syndrome (aHUS), an ultra-rare genetic disease characterized by thrombotic microangiopathy (TMA), the formation of blood clots in small blood vessels throughout the body. In two pivotal phase 2 studies, which initially enrolled 37more...
New Clinical Trial Data Show Substantial Improvement with Eculizumab (Soliris®) in Patients with STEC-HUS
11/3/12
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of 28-week data from all enrolled patients in a multi-center trial of eculizumab (Soliris®) in patients who developed Shiga-toxin-producing E. coli hemolytic uremic syndrome (STEC-HUS) during an outbreak in Germany from May 2011 to July 2011. In the study, eculizumab therapy was associated with rapid and sustained clinical improvements in thrombotic microangiopathy (more...
Alexion Reports Third Quarter 2012 Results
10/24/12
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) (Alexion or the Company) today announced financial results for the three and nine months ended September 30, 2012. Alexion reported net product sales of Soliris® (eculizumab) of $294.1 million in the third quarter of 2012, compared to $204.0 million for the same period in 2011. Revenue performance for the quarter reflected steady additions of new patients with paroxysmal nocturnalmore...
Alexion Pharmaceuticals to Report Third Quarter 2012 Results on Wednesday, October 24, 2012
10/17/12
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2012 on Wednesday, October 24, 2012 before the financial markets open. Following the release of the financial results, Alexion management will conduct a conference call and audio web cast on Wednesday, October 24, 2012, at 10:00 a.m. Eastern Time (ET). To participate in this conferencemore...

Alexion Pharmaceuticals

Newsroom Search

Media Contacts

All News Releases